Allergan Confident About Continued Growth, Swats Down Competition Concerns
Allergan’s fourth quarter earnings came in above analyst consensus, making up for the third quarter when revenue was below projections. The company is confident that it will experience continued sales growth in 2017, despite competitive pressures for key products.
You may also be interested in...
Part two of Scrip's preview of first quarter earnings: Recent launches, pricing strategies and biosimilar competition will be key themes as top-tier pharmaceutical companies continue to report first quarter performance.
Debt-fueled acquisitions helped Teva, Shire and Allergan report well-received fourth-quarter earnings. But sector circumstances have changed since 2016 and the ability to grow by debt-funded acquisition is now severely restricted.
Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.